The litigation centers on allegations that the San Francisco-based biopharmaceutical firm misled investors regarding the safety of its lead drug candidate, ARD-101. Designed to treat hyperphagia in Prader-Willi Syndrome, the drug faced significant scrutiny after Aardvark disclosed unexpected cardiac issues, specifically QRS prolongation, during clinical trials. The complaint alleges that the company's initial public offering documents and subsequent disclosures failed to adequately warn stakeholders that the drug's safety profile was far more precarious than official statements suggested.
In section Releases
Aardvark Therapeutics Investors Face October Deadline in Class Action
Investors who bought Aardvark Therapeutics stock between February 2025 and May 2026 are weighing their options as a securities class action lawsuit gains momentum. With a court-mandated deadline of October 13, 2026, shareholders who suffered losses during the company’s recent clinical setbacks are being urged to seek lead plaintiff status.
Financial fallout for shareholders followed two major regulatory developments in 2026. On February 27, the company voluntarily paused its Phase 3 HERO trial, triggering a 56% drop in share price. The situation intensified on May 14, when the FDA issued a full clinical hold on the company’s investigational new drug application, halting all studies and sending the stock down an additional 32.1%. Reed Kathrein, a partner at Hagens Berman Sobol Shapiro LLP, stated that the firm is actively investigating claims that the company materially overstated its commercial and regulatory prospects to the market.
Comments (0)
No comments yet. Be the first!